logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.
  • No Preview Available

Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])

PipelinePhase 3PeptideInvestigationalNot approved yet. Being tested in human clinical trials.
Generic:
Actinium
Sponsors:
AstraZeneca, Jonsson Comprehensive Cancer Center, Novartis Pharmaceuticals
Active US trials:
3
Earliest primary completion:
Dec 31, 2026
👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

On this page

  • Synopsis

Trials

  • Clinical trials
  • About this drug

Physicians

  • Physician Buzz
Similar Products
medicine
YONSA
medicine
ERLEADA
medicine
Xofigo
medicine
CABAZITAXEL
Synopsis
Generated with AlphaAI
Product:
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (3)

NCTPhaseStatusSponsorPrimary Completion
NCT07611110Phase 3RECRUITINGAstraZenecaJun 4, 2029
NCT07150715Phase 2RECRUITINGJonsson Comprehensive Cancer CenterOct 31, 2030
Status: Investigational
Not yet ratedEvidence: Not yet ratedWe have not yet attached proof for an evidence level.
NCT07150806Phase 1RECRUITINGJoshua PalmerDec 31, 2026

About this drug

Status
Active in clinical trials
Last Refreshed
Nov 13, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers

There isn't any reviews posted yet. You can be the first to review the product